DK1869171T4 - Virusrensning under anvendelse af ultrafiltrering - Google Patents
Virusrensning under anvendelse af ultrafiltrering Download PDFInfo
- Publication number
- DK1869171T4 DK1869171T4 DK06724513.4T DK06724513T DK1869171T4 DK 1869171 T4 DK1869171 T4 DK 1869171T4 DK 06724513 T DK06724513 T DK 06724513T DK 1869171 T4 DK1869171 T4 DK 1869171T4
- Authority
- DK
- Denmark
- Prior art keywords
- adenovirus
- virus
- buffer
- cells
- back pressure
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 132
- 238000000108 ultra-filtration Methods 0.000 title claims abstract description 49
- 238000004140 cleaning Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 147
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 123
- 239000012466 permeate Substances 0.000 claims abstract description 85
- 239000012465 retentate Substances 0.000 claims abstract description 57
- 238000004113 cell culture Methods 0.000 claims abstract description 16
- 239000000872 buffer Substances 0.000 claims description 72
- 230000008569 process Effects 0.000 claims description 53
- 238000009295 crossflow filtration Methods 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 45
- 101710163270 Nuclease Proteins 0.000 claims description 39
- 238000011026 diafiltration Methods 0.000 claims description 38
- 238000001914 filtration Methods 0.000 claims description 26
- 239000012510 hollow fiber Substances 0.000 claims description 26
- 239000006166 lysate Substances 0.000 claims description 22
- 238000011084 recovery Methods 0.000 claims description 21
- 238000005352 clarification Methods 0.000 claims description 19
- 238000012258 culturing Methods 0.000 claims description 16
- 230000002934 lysing effect Effects 0.000 claims description 15
- 238000005349 anion exchange Methods 0.000 claims description 14
- 238000005571 anion exchange chromatography Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 238000011146 sterile filtration Methods 0.000 claims description 11
- 238000005374 membrane filtration Methods 0.000 claims description 9
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 9
- 238000011210 chromatographic step Methods 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 53
- 238000004587 chromatography analysis Methods 0.000 abstract description 9
- 238000005199 ultracentrifugation Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 151
- 238000003306 harvesting Methods 0.000 description 36
- 108020004414 DNA Proteins 0.000 description 34
- 239000013598 vector Substances 0.000 description 34
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 24
- 229920004890 Triton X-100 Polymers 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 24
- 239000012528 membrane Substances 0.000 description 24
- 239000013504 Triton X-100 Substances 0.000 description 23
- 230000009089 cytolysis Effects 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 238000004007 reversed phase HPLC Methods 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- 239000003599 detergent Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 229920002684 Sepharose Polymers 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 238000001415 gene therapy Methods 0.000 description 11
- 239000012535 impurity Substances 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 108700019146 Transgenes Proteins 0.000 description 10
- 239000007983 Tris buffer Substances 0.000 description 10
- 230000002950 deficient Effects 0.000 description 10
- 238000011118 depth filtration Methods 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 230000006037 cell lysis Effects 0.000 description 6
- -1 cetylpyridium Chemical compound 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000001190 Q-PCR Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010364 biochemical engineering Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000012537 formulation buffer Substances 0.000 description 3
- 239000012145 high-salt buffer Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000001471 micro-filtration Methods 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000001902 propagating effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 229920003043 Cellulose fiber Polymers 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960001859 domiphen bromide Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 239000013017 sartobind Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- ZWEVPYNPHSPIFU-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxy-n-[3-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl-[4-(3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoyl]amino]propyl]hexanamide Chemical compound OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)N(CCCNC(=O)C(O)C(O)C(O)C(O)CO)CCCNC(=O)C(O)C(O)C(O)C(O)CO)C)C1(C)C(O)C2 ZWEVPYNPHSPIFU-UHFFFAOYSA-N 0.000 description 1
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 description 1
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
- 241000701124 Human adenovirus 35 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 241000712902 Lassa mammarenavirus Species 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102000007530 Neurofibromin 1 Human genes 0.000 description 1
- 108010085793 Neurofibromin 1 Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101000584831 Pseudoalteromonas phage PM2 Protein P6 Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 241001125929 Trisopterus luscus Species 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 102100022748 Wilms tumor protein Human genes 0.000 description 1
- BHATUINFZWUDIX-UHFFFAOYSA-N Zwittergent 3-14 Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O BHATUINFZWUDIX-UHFFFAOYSA-N 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 210000001776 amniocyte Anatomy 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003011 anion exchange membrane Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011035 continuous diafiltration Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- OJSUWTDDXLCUFR-YVKIRAPASA-N deoxy-bigchap Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)N(CCCNC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C)[C@@]2(C)[C@H](O)C1 OJSUWTDDXLCUFR-YVKIRAPASA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000012538 diafiltration buffer Substances 0.000 description 1
- SHFGJEQAOUMGJM-UHFFFAOYSA-N dialuminum dipotassium disodium dioxosilane iron(3+) oxocalcium oxomagnesium oxygen(2-) Chemical compound [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Al+3].[Al+3].[K+].[K+].[Fe+3].[Fe+3].O=[Mg].O=[Ca].O=[Si]=O SHFGJEQAOUMGJM-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000012789 harvest method Methods 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000011140 membrane chromatography Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 description 1
- 229920004905 octoxynol-10 Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000010451 perlite Substances 0.000 description 1
- 235000019362 perlite Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Claims (20)
1. Fremgangsmåde til rensning af et rekombinant adenovirus, omfattende et ultrafiltreringstrin, hvor retentatet indeholder viruset, kendetegnet ved, at et modtryk på mindst 5 kPa påsættes på permeatsiden.
2. Fremgangsmåde ifølge krav 1, hvor fremgangsmåden inden ultrafiltreringstrinnet omfatter følgende trin: a) dyrkning af celler, der er inficeret med viruset, b) tilsætning af nuklease til cellekulturen og derefter c) eventuelt lyse af cellerne til tilvejebringelse af et lysat indeholdende viruset og d) eventuelt klaring af lysatet, fortrinsvis ved dybfiltrering efterfulgt af membranfiltrering.
3. Fremgangsmåde ifølge ethvert af de foregående krav, ved hvilken ultrafiltreringen omfatter tangentiel strømningsfiltrering, fortrinsvis under anvendelse af et hult fibermodul.
4. Fremgangsmåde ifølge ethvert af de foregående krav, ved hvilken modtrykket på mindst 5 kPa påsættes med en pumpe, der tilvejebringer modtryk til permeatet.
5. Fremgangsmåde ifølge ethvert af de foregående krav, ved hvilken transmembrantrykket holdes under 20 kPa.
6. Fremgangsmåde ifølge ethvert af de foregående krav, ved hvilken ultrafiltreringen omfatter bufferskift i retentatet med en buffer indeholdende mellem 0,8 M og 2 M natriumchlorid eller et andet salt, der giver samme ionstyrke, og fortrinsvis bufferskift med en buffer med en ionstyrke som en buffer indeholdende mindre end 0,5 M NaCI.
7. Fremgangsmåde ifølge ethvert af de foregående krav, hvilken fremgangsmåde ikke omfatter et trin til størrelsesudelukkelseskromatografi.
8. Fremgangsmåde ifølge ethvert af de foregående krav, hvilken fremgangsmåde ikke omfatter et trin til anionbytningskromatografi eller anionbytningsfiltrering.
9. Fremgangsmåde ifølge ethvert af de foregående krav, hvilken fremgangsmåde er kendetegnet ved, at den ikke omfatter et kromatografitrin eller et ionbytningsfiltreringstrin.
10. Fremgangsmåde ifølge ethvert af de foregående krav, hvilken fremgangsmåde endvidere omfatter trin til yderligere rensning af det rekombinante adenovirus med mindst ét kromatografitrin.
11. Fremgangsmåde ifølge krav 10, ved hvilken fremgangsmåden omfatter et trin til anionbytningskromatografi, eventuelt udført ved påføring af den virusholdige opløsning på et ladet filter, der indeholder positivt ladede grupper.
12. Fremgangsmåde ifølge krav 10 eller 11, hvor fremgangsmåden omfatter et trin til størrelsesudelukkelseskromatografi.
13. Fremgangsmåde til rensning af et rekombinant adenovirus, hvilken fremgangsmåde i det væsentlige består af: a) dyrkning af celler, der er inficeret med det rekombinante adenovirus, b) lyse af cellerne og fjernelse og/eller fragmentering af fri nukleinsyre til tilvejebringelse af et lysat indeholdende det rekombinante adenovirus, c) klaring af lysatet til opnåelse af et adenoviruspræparat, d) udsættelse af adenoviruspræparatet for ultrafiltrering, hvor adenoviruspræparatet befinder sig i retentatet, til koncentrering af adenoviruspræparatet, e) udsættelse af adenoviruspræparatet fra trin d) for ultrafiltrering, hvor adenoviruspræparatet befinder sig i retentatet, og udskiftning deraf med mindst 5 diafiltreringsrumfang (DFV’er) buffer, hvor én DFV er rumfanget af retentatet efter koncentrering i trin d), f) fortrinsvis sterilfiltrering af adenoviruspræparat, hvilken fremgangsmåde er kendetegnet ved, at der i trin d) og e) påsættes et modtryk på mindst 5 kPa på permeatsiden.
14. Fremgangsmåde til rensning af et rekombinant adenovirus, hvilken fremgangsmåde i det væsentlige består af: a) dyrkning af celler, der er inficeret med det rekombinante adenovirus, b) lyse af cellerne og fjernelse og/eller fragmentering af fri nukleinsyre til tilvejebringelse af et lysat indeholdende det rekombinante adenovirus, c) klaring af lysatet til opnåelse af et adenoviruspræparat, d) udsættelse af adenoviruspræparatet fra trin c) for ultrafiltrering, hvor adenovirus-præparatet befinder sig i retentatet, og udskiftning deraf med mindst 5 diafiltreringsrumfang (DFV’er) buffer, hvor én DFV er rumfanget af adenoviruspræparatet efter c), e) fortrinsvis sterilfiltrering af adenoviruspræparatet, hvilken fremgangsmåde er kendetegnet ved, at i trin d) påsættes et modtryk på mindst 5 kPa på permeatsiden.
15. Fremgangsmåde ifølge krav 13 eller 14, ved hvilken trin b) omfatter: b, i) tilsætning af nuklease til cellekulturen og derefter b, ii) lyse af cellerne til tilvejebringelse af et lysat indeholdende det rekombinante adenovirus.
16. Fremgangsmåde ifølge ethvert af kravene 13-15, ved hvilken ultrafiltreringen omfatter tangentiel strømningsfiltrering, fortrinsvis under anvendelse af et hult fibermodul.
17. Fremgangsmåde ifølge ethvert af kravene 13-16, ved hvilken modtrykket påsættes med en pumpe, der tilvejebringer modtryk til permeatet.
18. Fremgangsmåde ifølge ethvert af kravene 13-17, ved hvilken transmembrantrykket under ultrafiltreringen holdes under 20 kPa.
19. Fremgangsmåde ifølge ethvert af kravene 13-18, ved hvilken bufferskiftet med retentatet omfatter bufferskift med buffere med forskellig ionstyrke, herunder bufferskift med en buffer indeholdende mellem 0,8 M og 2 M natriumchlorid eller et andet salt, der giver samme ionstyrke, og fortrinsvis efterfølgende bufferskift med en buffer med en ionstyrke som en buffer indeholdende mindre end 0,5 M NaCI.
20. Fremgangsmåde til forøgelse af udvindingen og/eller udbyttet af rekombinant adenovirus under et ultrafiltreringstrin, hvor retentatet indeholder det rekombinante adenovirus, hvilken fremgangsmåde er kendetegnet ved, at et modtryk på mindst 5 kPa påsættes på permeatsiden.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67006405P | 2005-04-11 | 2005-04-11 | |
EP05102842 | 2005-04-11 | ||
PCT/EP2006/003722 WO2006108707A1 (en) | 2005-04-11 | 2006-04-11 | Virus purification using ultrafiltration |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1869171T3 DK1869171T3 (da) | 2009-02-16 |
DK1869171T4 true DK1869171T4 (da) | 2016-01-18 |
Family
ID=36572264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06724513.4T DK1869171T4 (da) | 2005-04-11 | 2006-04-11 | Virusrensning under anvendelse af ultrafiltrering |
Country Status (10)
Country | Link |
---|---|
US (1) | US8574595B2 (da) |
EP (1) | EP1869171B2 (da) |
CN (1) | CN101155915B (da) |
AT (1) | ATE412737T1 (da) |
AU (1) | AU2006233800B2 (da) |
CA (1) | CA2602944C (da) |
DE (1) | DE602006003420D1 (da) |
DK (1) | DK1869171T4 (da) |
ES (1) | ES2317517T5 (da) |
WO (1) | WO2006108707A1 (da) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005305347A1 (en) * | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying of adenoviral vectors |
WO2007110409A1 (en) * | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
FR2907453B1 (fr) | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
US20080131955A1 (en) * | 2006-11-30 | 2008-06-05 | Canon U.S. Life Sciences, Inc. | Method of Separating Target DNA from Mixed DNA |
WO2009044414A1 (en) * | 2007-10-02 | 2009-04-09 | Gima S.P.A. | Process and system for the industrial scale purification of bacteriophages intended for bacteriophage therapy |
DK2242479T3 (da) * | 2007-12-28 | 2012-01-02 | Baxter Int | Modtryksfiltrering af proteiner |
US10273502B2 (en) * | 2008-06-18 | 2019-04-30 | Oxford Biomedica (Uk) Limited | Virus purification |
PL2350268T3 (pl) * | 2008-11-03 | 2015-05-29 | Crucell Holland Bv | Sposób wytwarzania wektorów adenowirusowych |
FR2944292B1 (fr) | 2009-04-08 | 2013-08-23 | Sanofi Pasteur | Procede de purification du virus rabique |
WO2011045378A1 (en) | 2009-10-15 | 2011-04-21 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
ES2445713T3 (es) | 2009-10-15 | 2014-03-04 | Crucell Holland B.V. | Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular |
NZ601424A (en) | 2010-02-15 | 2014-07-25 | Crucell Holland Bv | Method for the production of ad26 adenoviral vectors |
BR112012026095A2 (pt) | 2010-04-14 | 2015-09-15 | Emd Millipore Corp | métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos. |
PL2575872T3 (pl) * | 2010-06-01 | 2021-02-22 | Seqirus UK Limited | Zatężanie antygenów szczepionkowych grypy bez liofilizacji |
SG188947A1 (en) | 2010-08-12 | 2013-06-28 | Yisheng Biopharma Holdings Ltd | Method for reducing dna impurities in viral compositions |
CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
MX354752B (es) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria. |
MX2013010737A (es) * | 2011-03-25 | 2014-03-12 | Genentech Inc | Novedosos metodos de purificacion de proteinas. |
CA2841831C (en) * | 2011-08-05 | 2019-12-31 | John Bell | Methods and compositions for production of vaccinia virus |
CN102688485A (zh) * | 2011-09-16 | 2012-09-26 | 扬州优邦生物制药有限公司 | 一种猪细小病毒灭活疫苗的制备方法 |
US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
CA2896931A1 (en) * | 2012-01-09 | 2013-07-18 | Sanofi Pasteur Biologics, Llc | Purification of flaviviruses |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
SG11201405228VA (en) | 2012-03-12 | 2014-11-27 | Crucell Holland Bv | Batches of recombinant adenovirus with altered terminal ends |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
EP2827895B1 (en) | 2012-03-22 | 2017-08-09 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
CN103923883A (zh) * | 2013-01-16 | 2014-07-16 | 辽宁成大生物股份有限公司 | 一种流感病毒的浓缩、纯化方法 |
AP2015008815A0 (en) | 2013-04-25 | 2015-10-31 | Crucell Holland Bv | Stabilized soluble prefusion rsv f polypeptides |
MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
WO2015010030A1 (en) * | 2013-07-18 | 2015-01-22 | Children's Hospital Medical Center | Methods of improving titer in transfection-based production systems using eukaryotic cells |
CN103601793A (zh) * | 2013-10-23 | 2014-02-26 | 乾元浩生物股份有限公司 | 一种禽用疫苗抗原纯化的方法 |
CA3140009C (en) * | 2014-05-13 | 2023-09-05 | Amgen Inc. | Process control systems and methods for use with filters and filtration processes |
CA3159833A1 (en) | 2014-05-21 | 2015-11-26 | Unchained Labs | Systems and methods for exchange of buffer solutions |
CA2955877A1 (en) * | 2014-07-24 | 2016-01-28 | Janssen Vaccines & Prevention B.V. | Process for the purification of poliovirus from cell cultures |
SI3283634T1 (sl) | 2015-04-14 | 2019-08-30 | Janssen Vaccines & Prevention B.V. | Rekombinantni adenovirus, ki izraža dva transgena z dvosmernim promotorjem |
EP3319634B1 (en) | 2015-07-07 | 2019-08-21 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
JP7189014B2 (ja) | 2015-07-07 | 2022-12-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Rsvに対するワクチン |
JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Rsvに対するワクチン |
DK3439672T3 (da) | 2016-04-05 | 2021-02-15 | Janssen Vaccines & Prevention Bv | Stabiliserede opløselige præfusions-rsv-f-proteiner |
KR102573534B1 (ko) | 2016-05-12 | 2023-08-31 | 얀센 백신스 앤드 프리벤션 비.브이. | 강력하고 균형 잡힌 양방향성 프로모터 |
ES2836598T3 (es) | 2016-05-30 | 2021-06-25 | Janssen Vaccines & Prevention Bv | Proteínas F de RSV prefusión estabilizadas |
CN109312362B (zh) | 2016-06-20 | 2022-06-28 | 扬森疫苗与预防公司 | 有效和平衡的双向启动子 |
JP7229151B2 (ja) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hpvワクチン |
WO2018115308A1 (en) * | 2016-12-22 | 2018-06-28 | Blue Sky Vaccines Gmbh | Method for purifying virus |
AU2018217935B2 (en) | 2017-02-09 | 2020-04-30 | Janssen Vaccines & Prevention B.V. | Potent and short promoter for expression of heterologous genes |
EP3625334A1 (en) * | 2017-05-15 | 2020-03-25 | c-LEcta GmbH | Enzyme products |
JP2020519663A (ja) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Rsv感染に対する防御免疫を誘導するための方法及び組成物 |
CN107603959A (zh) * | 2017-08-30 | 2018-01-19 | 四川大学 | 提高缓冲液盐离子浓度纯化病毒的方法 |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
GB201806736D0 (en) * | 2018-04-25 | 2018-06-06 | Ge Healthcare Bioprocess R&D Ab | Method for virus purification |
CN111454914A (zh) * | 2019-01-18 | 2020-07-28 | 嘉兴安宇生物科技有限公司 | 一种腺病毒快速纯化方法 |
US20220090140A1 (en) * | 2019-05-14 | 2022-03-24 | Janssen Biotech, Inc. | Efficient Impurity Removal Using A Diafiltration Process |
CN110129287B (zh) * | 2019-05-15 | 2023-07-14 | 青岛蔚蓝生物制品有限公司 | 一种猪伪狂犬病毒双重超滤系统及纯化方法 |
CN111394390A (zh) * | 2020-03-26 | 2020-07-10 | 赛诺(深圳)生物医药研究有限公司 | 用于新型冠状病毒基因疫苗的批量生产重组腺病毒的方法 |
CN111575244B (zh) * | 2020-05-06 | 2021-07-23 | 江苏金迪克生物技术股份有限公司 | 一种低Vero细胞残留DNA狂犬病疫苗原液的制备方法 |
CN112226418B (zh) * | 2020-09-25 | 2022-07-08 | 阜外华中心血管病医院 | 重组腺相关病毒纯化方法 |
WO2022123006A1 (en) * | 2020-12-10 | 2022-06-16 | Astrazeneca Uk Limited | Methods of purifying adenovirus |
CN112899242A (zh) * | 2021-02-03 | 2021-06-04 | 苏州博腾生物制药有限公司 | 慢病毒纯化工艺 |
CN113373120B (zh) * | 2021-06-18 | 2022-04-26 | 浙江康佰裕生物科技有限公司 | Gmp级逆转录病毒载体的纯化方法与应用 |
CN113817689B (zh) * | 2021-11-22 | 2023-10-03 | 北京艺妙神州医药科技有限公司 | 慢病毒纯化工艺 |
CN115747017B (zh) * | 2022-10-25 | 2023-06-09 | 上海华新生物高技术有限公司 | 一种腺病毒纯化装置 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE434914B (sv) * | 1975-07-07 | 1984-08-27 | Jonsson U R S | Forfarande for att ur en suspension av bakterier och ett vetskeformigt medium genom filtrering avskilja mediet under samtidig anrikning av bakterierna |
US4435289A (en) * | 1981-12-23 | 1984-03-06 | Romicon, Inc. | Series ultrafiltration with pressurized permeate |
US5173418A (en) * | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
US4808315A (en) * | 1986-04-28 | 1989-02-28 | Asahi Kasei Kogyo Kabushiki Kaisha | Porous hollow fiber membrane and a method for the removal of a virus by using the same |
FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
FR2716682B1 (fr) * | 1994-01-28 | 1996-04-26 | Centre Nat Rech Scient | Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations. |
US5851806A (en) * | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
CA2192442C (en) * | 1994-06-10 | 2007-09-25 | Imre Kovesdi | Complementary adenoviral vector systems and cell lines |
SE9500724D0 (sv) | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
US5965541A (en) * | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
IL122614A0 (en) * | 1995-06-15 | 1998-08-16 | Introgene Bv | Packaging systems for human recombinant adenovirus to be used in gene therapy |
FR2737730B1 (fr) * | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
US5840565A (en) * | 1995-08-22 | 1998-11-24 | The Regents Of The University Of California | Methods for enhancing the production of viral vaccines in PKR-deficient cell culture |
US6143548A (en) | 1995-08-30 | 2000-11-07 | Genzyme Corporation | Chromatographic purification of adeno-associated virus (AAV) |
US5837511A (en) * | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) * | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
AU3447097A (en) * | 1996-07-01 | 1998-01-21 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant adenovirus |
FR2751343B1 (fr) * | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
DE69737107T2 (de) * | 1996-11-20 | 2007-07-12 | Introgen Therapeutics Inc., Austin | Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren |
US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
EP1731598A1 (en) | 1997-01-31 | 2006-12-13 | Schering Corporation | Methods for cultivating cells and propagating viruses |
US6168944B1 (en) * | 1997-01-31 | 2001-01-02 | Schering Corporation | Methods for cultivating cells and propagating viruses |
JP2000509614A (ja) | 1997-03-04 | 2000-08-02 | バクスター インターナショナル インコーポレイテッド | アデノウイルスe1−相補性細胞系 |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6020191A (en) * | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US5947689A (en) * | 1997-05-07 | 1999-09-07 | Scilog, Inc. | Automated, quantitative, system for filtration of liquids having a pump controller |
AU748730B2 (en) * | 1997-08-28 | 2002-06-13 | Cheil Jedang Corporation | An attenuated Japanese encephalitis virus adapted to vero cell and a Japanese encephalitis vaccine |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
KR100912362B1 (ko) | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
US5981225A (en) * | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
IL139040A0 (en) * | 1998-04-22 | 2001-11-25 | Genvec Inc | Efficient purification of adenovirus |
US5994134A (en) * | 1998-05-04 | 1999-11-30 | Canji, Inc. | Viral production process |
US6113913A (en) * | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
US6342384B1 (en) * | 1998-08-21 | 2002-01-29 | The University Of Va Patent Foundation | Production of adenoviral vectors using serum-free suspension cell culture in a hollow fiber system |
ATE421337T1 (de) | 1998-11-16 | 2009-02-15 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
JP2003523169A (ja) * | 1998-12-31 | 2003-08-05 | アバンテイス・フアルマ・エス・アー | ウイルス粒子の分離法 |
WO2000050573A1 (fr) | 1999-02-22 | 2000-08-31 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
US6120820A (en) * | 1999-02-22 | 2000-09-19 | Land O'lakes, Inc. | Method of modifying the color of a dairy material |
AU777041B2 (en) | 1999-05-17 | 2004-09-30 | Crucell Holland B.V. | Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35 |
US6492169B1 (en) * | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
US20020041884A1 (en) | 2000-03-07 | 2002-04-11 | Evans Robert K. | Adenovirus formulations |
US6168941B1 (en) | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
DE10022258A1 (de) * | 2000-05-08 | 2001-11-15 | Bayer Ag | Reinigung von Proteineinschlusskörpern durch Querstrom-Mikrofiltration |
AU9456201A (en) | 2000-09-15 | 2002-03-26 | Merck & Co Inc | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
US6365395B1 (en) * | 2000-11-03 | 2002-04-02 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
US20020064860A1 (en) | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
IL152420A0 (en) | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
JP4559026B2 (ja) | 2001-03-01 | 2010-10-06 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 単一ユニット操作におけるアデノウイルス感染細胞の濃縮および溶解 |
CA2776522C (en) | 2001-10-01 | 2015-02-17 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Development of a preventive vaccine for filovirus infection in primates |
JP4550421B2 (ja) | 2001-12-12 | 2010-09-22 | メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド | ウイルスの保存のための組成物 |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
CA2478932A1 (en) | 2002-03-29 | 2003-10-16 | Merck & Co., Inc. | Large scale methods of producing adenovirus and adenovirus seed stocks |
ES2335657T3 (es) | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
ATE405663T1 (de) | 2002-04-25 | 2008-09-15 | Crucell Holland Bv | Stabile adenovirale vektoren und methoden für deren vermehrung |
DE60335672D1 (de) | 2002-05-14 | 2011-02-17 | Merck Sharp & Dohme | Verfahren zur reinigung von adenovirus |
US20050095705A1 (en) | 2003-04-15 | 2005-05-05 | Michael Kadan | Method for production of oncolytic adenoviruses |
AU2004249199B2 (en) * | 2003-06-18 | 2008-07-24 | Onyx Pharmaceuticals, Inc. | Method for purifying virus |
ES2329607T3 (es) * | 2004-02-23 | 2009-11-27 | Crucell Holland B.V. | Metodos de purificacion de virus. |
-
2006
- 2006-04-11 AT AT06724513T patent/ATE412737T1/de active
- 2006-04-11 AU AU2006233800A patent/AU2006233800B2/en active Active
- 2006-04-11 ES ES06724513.4T patent/ES2317517T5/es active Active
- 2006-04-11 WO PCT/EP2006/003722 patent/WO2006108707A1/en not_active Application Discontinuation
- 2006-04-11 DE DE602006003420T patent/DE602006003420D1/de active Active
- 2006-04-11 EP EP06724513.4A patent/EP1869171B2/en active Active
- 2006-04-11 CN CN2006800118153A patent/CN101155915B/zh active Active
- 2006-04-11 US US11/909,955 patent/US8574595B2/en active Active
- 2006-04-11 CA CA2602944A patent/CA2602944C/en active Active
- 2006-04-11 DK DK06724513.4T patent/DK1869171T4/da active
Also Published As
Publication number | Publication date |
---|---|
EP1869171B1 (en) | 2008-10-29 |
EP1869171A1 (en) | 2007-12-26 |
DE602006003420D1 (de) | 2008-12-11 |
AU2006233800A1 (en) | 2006-10-19 |
CA2602944A1 (en) | 2006-10-19 |
CN101155915B (zh) | 2013-12-04 |
US8574595B2 (en) | 2013-11-05 |
US20090123989A1 (en) | 2009-05-14 |
ATE412737T1 (de) | 2008-11-15 |
EP1869171B2 (en) | 2015-10-14 |
AU2006233800B2 (en) | 2011-07-07 |
ES2317517T5 (es) | 2016-01-21 |
DK1869171T3 (da) | 2009-02-16 |
CN101155915A (zh) | 2008-04-02 |
ES2317517T3 (es) | 2009-04-16 |
WO2006108707A1 (en) | 2006-10-19 |
CA2602944C (en) | 2015-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1869171T4 (da) | Virusrensning under anvendelse af ultrafiltrering | |
EP1780269B1 (en) | Virus purification methods | |
US8460920B2 (en) | Method for the purification of adenovirus particles | |
US8470585B2 (en) | Process for adenovirus purification from high cell density cultures |